IL-33 and IL-33-derived DC-based tumor immunotherapy

• Published in: Experimental & molecular medicine Vol. 56; no. 6; pp. 1340 - 1347
• Main Authors: Kang, Myeong-Ho, Bae, Yong-Soo
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01-06-2024; Springer Nature B.V; Nature Publishing Group
• Subjects: 13/21; 13/31; 631/250/2504/133/2505; 631/250/251/1567; 64/60; Animals; Antigen-presenting cells; Antitumor activity; Artificial intelligence; Biomedical and Life Sciences; Biomedicine; Cancer; Cancer therapies; Cancer Vaccines - immunology; CD8 antigen; Cell activation; Cytokines; Dendritic cells; Dendritic Cells - immunology; Dendritic Cells - metabolism; Humans; Immunogenicity; Immunotherapy; Immunotherapy - methods; Infections; Interleukin-33 - immunology; Interleukin-33 - metabolism; Lymphocytes T; Medical Biochemistry; Molecular Medicine; Neoplasms - immunology; Neoplasms - therapy; Review; Review Article; Stem Cells; Tumors
• ISSN: 2092-6413; 1226-3613; 2092-6413
• DOI: 10.1038/s12276-024-01249-4

Interleukin-33 (IL-33), a member of the IL-1 family, is a cytokine released in response to tissue damage and is recognized as an alarmin. The multifaceted roles of IL-33 in tumor progression have sparked controversy within the scientific community. However, most findings generally indicate that endogenous IL-33 has a protumor effect, while exogenous IL-33 often has an antitumor effect in most cases. This review covers the general characteristics of IL-33 and its effects on tumor growth, with detailed information on the immunological mechanisms associated with dendritic cells (DCs). Notably, DCs possess the capability to uptake, process, and present antigens to CD8
+
T cells, positioning them as professional antigen-presenting cells. Recent findings from our research highlight the direct association between the tumor-suppressive effects of exogenous IL-33 and a novel subset of highly immunogenic cDC1s. Exogenous IL-33 induces the development of these highly immunogenic cDC1s through the activation of other ST2
+
immune cells both in vivo and in vitro. Recognizing the pivotal role of the immunogenicity of DC vaccines in DC-based tumor immunotherapy, we propose compelling methods to enhance this immunogenicity through the addition of IL-33 and the promotion of highly immunogenic DC generation.
Exogenous IL-33: Unveiling Tumor-Suppressive Effects on cDC1s
Interleukin-33 (IL-33), a protein that helps the body in combating infections, plays a double role in cancer growth, says a study by Kang and Bae. The research found that IL-33 can both help and hinder cancer growth, contingent upon its concentration and the specific infection-fighting (immune?) cells it interacts with. The study, done on mice, showed that lower concentrations of IL-33 facilitate cancer grow by increasing certain infection-fighting (immune?) cell groups and causing cell multiplication. Conversely, higher concentrations of IL-33 counteract these effects, triggering anti-cancer responses by activating other infection-fighting (immune?) cells. The researchers concluded that IL-33 holds potential for cancer therapy, either through direct injection or by fostering the production of potent infection-fighting (immune?) cells for vaccination. Future research will delve into the implications of these findings for human cancer treatment. "This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author."